1. Home
  2. BEAM vs CRAI Comparison

BEAM vs CRAI Comparison

Compare BEAM & CRAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BEAM
  • CRAI
  • Stock Information
  • Founded
  • BEAM 2017
  • CRAI 1965
  • Country
  • BEAM United States
  • CRAI United States
  • Employees
  • BEAM N/A
  • CRAI N/A
  • Industry
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • CRAI Other Consumer Services
  • Sector
  • BEAM Health Care
  • CRAI Consumer Discretionary
  • Exchange
  • BEAM Nasdaq
  • CRAI Nasdaq
  • Market Cap
  • BEAM 1.7B
  • CRAI 1.4B
  • IPO Year
  • BEAM 2020
  • CRAI 1998
  • Fundamental
  • Price
  • BEAM $25.79
  • CRAI $181.63
  • Analyst Decision
  • BEAM Strong Buy
  • CRAI Buy
  • Analyst Count
  • BEAM 11
  • CRAI 1
  • Target Price
  • BEAM $49.40
  • CRAI $235.00
  • AVG Volume (30 Days)
  • BEAM 2.3M
  • CRAI 123.5K
  • Earning Date
  • BEAM 11-04-2025
  • CRAI 10-30-2025
  • Dividend Yield
  • BEAM N/A
  • CRAI 1.09%
  • EPS Growth
  • BEAM N/A
  • CRAI 44.21
  • EPS
  • BEAM N/A
  • CRAI 8.27
  • Revenue
  • BEAM $60,272,000.00
  • CRAI $712,913,000.00
  • Revenue This Year
  • BEAM N/A
  • CRAI $9.01
  • Revenue Next Year
  • BEAM $18.95
  • CRAI $4.26
  • P/E Ratio
  • BEAM N/A
  • CRAI $21.84
  • Revenue Growth
  • BEAM N/A
  • CRAI 9.28
  • 52 Week Low
  • BEAM $13.53
  • CRAI $152.57
  • 52 Week High
  • BEAM $35.25
  • CRAI $214.66
  • Technical
  • Relative Strength Index (RSI)
  • BEAM 57.00
  • CRAI 35.88
  • Support Level
  • BEAM $23.53
  • CRAI $173.27
  • Resistance Level
  • BEAM $28.75
  • CRAI $208.46
  • Average True Range (ATR)
  • BEAM 1.76
  • CRAI 5.76
  • MACD
  • BEAM -0.13
  • CRAI -2.34
  • Stochastic Oscillator
  • BEAM 50.50
  • CRAI 23.76

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About CRAI CRA International Inc.

CRA International Inc is a U.S.-based advisory firm that provides economic, financial, and management consultancy services. The company advises clients on economic and financial issues relating to litigation and regulatory proceedings and helps businesses set important business strategies and solve performance-related issues. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. CRA International generates majority of its revenue from the United States, while it also has its presence in United Kingdom and Other Countries.

Share on Social Networks: